PMC:4693303 / 23351-23961 JSONTXT

{"project":"TEST0","denotations":[{"id":"26752867-235-241-1465724","span":{"begin":459,"end":461},"obj":"[\"25972518\"]"}],"text":"The research focused on the pharmaceutical treatment of Ebola infection has produced somewhat disappointing results. One candidate drug, TKM-Ebola, after showing promise in primates, has subsequently been demonstrated to be ineffective in treating human Ebola infection.[54] Although the other experimental IgG-based monoclonal antibody-based drug ZMapp has shown good efficacy in primates,[55] there is no compelling evidence that it is effective in humans.[56] In addition, despite a poorly defined safety profile, the drug recently received fast track approval by the Food and Drug Administration (FDA).[57]"}

{"project":"2_test","denotations":[{"id":"26752867-25972518-60482790","span":{"begin":459,"end":461},"obj":"25972518"}],"text":"The research focused on the pharmaceutical treatment of Ebola infection has produced somewhat disappointing results. One candidate drug, TKM-Ebola, after showing promise in primates, has subsequently been demonstrated to be ineffective in treating human Ebola infection.[54] Although the other experimental IgG-based monoclonal antibody-based drug ZMapp has shown good efficacy in primates,[55] there is no compelling evidence that it is effective in humans.[56] In addition, despite a poorly defined safety profile, the drug recently received fast track approval by the Food and Drug Administration (FDA).[57]"}